EP0131942B1 - Anthracyclin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika - Google Patents

Anthracyclin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika Download PDF

Info

Publication number
EP0131942B1
EP0131942B1 EP84108305A EP84108305A EP0131942B1 EP 0131942 B1 EP0131942 B1 EP 0131942B1 EP 84108305 A EP84108305 A EP 84108305A EP 84108305 A EP84108305 A EP 84108305A EP 0131942 B1 EP0131942 B1 EP 0131942B1
Authority
EP
European Patent Office
Prior art keywords
acid
roa
formula
cytorhodin
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP84108305A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0131942A1 (de
Inventor
Gerhard Dr. Huber
Hans Gerd Dr. Berscheid
Hans-Wolfram Dr. Fehlhaber
Hans Peter Dr. Kraemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to AT84108305T priority Critical patent/ATE30727T1/de
Publication of EP0131942A1 publication Critical patent/EP0131942A1/de
Application granted granted Critical
Publication of EP0131942B1 publication Critical patent/EP0131942B1/de
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond

Definitions

  • the invention further relates to a process for the preparation of the compounds of the formula which is characterized in that the residue, which is deposited according to DE-A-33 230 250 by fermentation of the microorganism strain Y-11472 (deposited on May 24, 1983 under the entry number DSM 2658 in the “German Collection of Microorganisms •) and extraction of the mycelium and the culture filtrate with an organic solvent is treated with a dilute strong or medium strong acid.
  • the compounds produced in this way are notable for high cytostatic activity.
  • the strain Streptomyces Y-11472 is fermented in a nutrient medium in the customary manner, with temperatures of approximately 24-40 ° C., a pH of 6.5-8.5 and aerobic conditions being maintained.
  • the anthracycline compounds are extracted from the mycelium by extraction, for. B. extracted with aqueous acetone at pH 3.5, the acetone removed and the aqueous phase extracted at pH 7.5 with ethyl acetate.
  • the culture liquid is extracted at a pH of 7.5, preferably with ethyl acetate.
  • the ethyl acetate extracts from the mycelium and the culture filtrate are combined and evaporated to dryness to give a crude residue.
  • the residue thus obtained can now be subjected to an acid treatment according to the invention. However, the residue is preferably worked up further, as also described in the abovementioned German patent application.
  • the crude residue is dissolved in toluene and extracted with an acetate buffer (pH 3.5), whereby a toluene phase and an aqueous phase are obtained.
  • the aqueous phase is worked up further in the following manner: after adjusting the pH to 7.5, the mixture is extracted again with ethyl acetate and the ethyl acetate phase is concentrated, giving a so-called cytorhodin crude mixture.
  • anthracycline derivatives with cytostatic activity can be obtained from this crude mixture by chromatography.
  • Anthracyclines are obtained by treating the crude residue described above or the so-called raw cytorhodin mixture with a dilute strong or medium-strong acid.
  • acids are such.
  • the acid treatment is carried out at room temperature or slightly elevated temperature, preferably 37 ° C.
  • the reaction time can be 0.5 to several hours.
  • the desired compounds are isolated from the reaction medium by extraction and separated by column chromatography, preferably on silica gel.
  • the cytorhodins according to the invention are notable for high cytostatic activity and, in the cell proliferation test on L 1210 leukemia cells, gave the following effect:
  • the radioactivity built into the DNA is determined after adding 5 ml of scintillation fluid. The results are given as ratios of the scintillation index after incubation with test substance in percent of the untreated control.
  • the dose-response curve is determined from the measured values thus obtained and the IC 50 , ie the concentration which, under test conditions, reduces the incorporation of radioactive thymidine by 50% compared to the control. determined.
  • the combined fractions are mixed with a 5% aqueous Na 2 HPO 4 solution until the chloroform phase is separated off, washed with 1 volume of Na 2 HP0 4 solution and water, dried over anhydrous sodium sulfate, concentrated in vacuo and precipitated with hexane .
  • cytorhodin complex 1.1 g of cytorhodin complex are dissolved in 60 ml of 0.2 N formic acid and heated to 37 ° C. for 24 hours.
  • the solution which according to the thin-layer chromatogram contains the cytorhodins S and T, is adjusted to pH 7.5 with 1N NaOH and worked up as in Example 1.
  • a solution of 0.5 g cytorhodin complex in 28 ml H 2 0 is mixed with stirring with 0.64 ml trifluoroacetic acid and then left to stand for 4 hours at room temperature.
  • the solution is worked up as in Examples 1 and 2 on cytorhodin S and T.
  • the signals marked with an asterisk in the figures come from low-molecular impurities in the% range and from solvent residues.
  • Mass spectra were measured on the MS-902 S, AEI mass spectrometer using an FAB (Fast Atom Bombardment) ion source.
  • FAB Fluor Atom Bombardment
  • the substances were introduced into the ion source in a matrix of thioglycerin, sometimes with the addition of ammonium chloride.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP84108305A 1983-07-19 1984-07-14 Anthracyclin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika Expired EP0131942B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT84108305T ATE30727T1 (de) 1983-07-19 1984-07-14 Anthracyclin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als cytostatika.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3325957 1983-07-19
DE19833325957 DE3325957A1 (de) 1983-07-19 1983-07-19 Anthracyclin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als cytostatika

Publications (2)

Publication Number Publication Date
EP0131942A1 EP0131942A1 (de) 1985-01-23
EP0131942B1 true EP0131942B1 (de) 1987-11-11

Family

ID=6204326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84108305A Expired EP0131942B1 (de) 1983-07-19 1984-07-14 Anthracyclin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika

Country Status (20)

Country Link
US (1) US4737583A (sv)
EP (1) EP0131942B1 (sv)
JP (1) JPS6048994A (sv)
KR (1) KR850001226A (sv)
AR (1) AR240460A1 (sv)
AT (1) ATE30727T1 (sv)
AU (1) AU562684B2 (sv)
CA (1) CA1246062A (sv)
DE (2) DE3325957A1 (sv)
DK (1) DK352884A (sv)
ES (1) ES8600326A1 (sv)
FI (1) FI75173C (sv)
GR (1) GR81549B (sv)
HU (1) HU196422B (sv)
IL (1) IL72432A0 (sv)
NO (1) NO162023C (sv)
NZ (1) NZ208917A (sv)
PH (1) PH24156A (sv)
PT (1) PT78932A (sv)
ZA (1) ZA845538B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6117597A (ja) * 1984-07-03 1986-01-25 Microbial Chem Res Found アントラサイクリン化合物
DE3425357A1 (de) * 1984-07-10 1986-01-23 Hoechst Ag, 6230 Frankfurt 1-hydroxy-cytorhodine, ein mikrobiologisches verfahren zu ihrer herstellung und ihre verwendung als cytostatika
DE3524117A1 (de) * 1985-07-05 1987-02-05 Hoechst Ag Neue anthracyclin-tetrasaccharide, ein verfahren zu ihrer herstellung und ihre verwendung als cytostatik
JPH0822869B2 (ja) * 1986-06-25 1996-03-06 ヘキストジヤパン株式会社 サイトロジンｓ誘導体およびそれを含有する抗癌剤
DE3641833A1 (de) * 1986-12-08 1988-06-09 Behringwerke Ag Zytostatisch wirksame anthracyclinderivate
DE3709337A1 (de) * 1987-03-21 1988-10-13 Hoechst Ag Neue anthracyclin-glycoside, ein verfahren zu ihrer herstellung und ihre verwendung als cytostatika
DE3733885A1 (de) * 1987-10-07 1989-04-27 Hoechst Ag Neue anthracyclin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3801178A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung
DE3819092A1 (de) * 1988-06-04 1989-12-14 Behringwerke Ag Zytostatisch wirksame anthracyclinderivate
US20050208037A1 (en) * 2003-10-21 2005-09-22 Board Of Regents, The University Of Texas System Thioredoxin increases redox-cycling of anticancer agents thereby sensitizes cancer cells to apoptosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0110155A1 (en) * 1982-11-02 1984-06-13 Microbial Chemistry Research Foundation Novel anthracycline derivatives, a process for preparing the same by a microorganism strain, the novel strain streptomyces cyaneus, and use of the anthracycline derivatives as medicaments
EP0131181A2 (de) * 1983-06-25 1985-01-16 Hoechst Aktiengesellschaft Anthracyclin-Derivate, ein mikrobiologisches Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023679B2 (ja) * 1979-07-13 1985-06-08 メルシャン株式会社 ロドマイシン群抗生物質とその製造法
JPS59148795A (ja) * 1983-02-08 1984-08-25 Microbial Chem Res Found アントラサイクリン化合物、その製造法およびその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0110155A1 (en) * 1982-11-02 1984-06-13 Microbial Chemistry Research Foundation Novel anthracycline derivatives, a process for preparing the same by a microorganism strain, the novel strain streptomyces cyaneus, and use of the anthracycline derivatives as medicaments
EP0131181A2 (de) * 1983-06-25 1985-01-16 Hoechst Aktiengesellschaft Anthracyclin-Derivate, ein mikrobiologisches Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika

Also Published As

Publication number Publication date
PT78932A (de) 1984-08-01
FI75173C (sv) 1988-05-09
NO842938L (no) 1985-01-21
US4737583A (en) 1988-04-12
JPS6048994A (ja) 1985-03-16
HU196422B (en) 1988-11-28
AU3082384A (en) 1985-01-24
ES534377A0 (es) 1985-10-01
NZ208917A (en) 1988-03-30
DE3467350D1 (en) 1987-12-17
HUT36837A (en) 1985-10-28
FI75173B (fi) 1988-01-29
DE3325957A1 (de) 1985-02-07
JPH0150714B2 (sv) 1989-10-31
ZA845538B (en) 1985-02-27
ATE30727T1 (de) 1987-11-15
FI842877A0 (fi) 1984-07-17
NO162023B (no) 1989-07-17
AR240460A1 (es) 1990-04-30
CA1246062A (en) 1988-12-06
DK352884D0 (da) 1984-07-18
NO162023C (no) 1989-10-25
EP0131942A1 (de) 1985-01-23
ES8600326A1 (es) 1985-10-01
IL72432A0 (en) 1984-11-30
GR81549B (sv) 1984-12-11
AU562684B2 (en) 1987-06-18
KR850001226A (ko) 1985-03-16
FI842877A (fi) 1985-01-20
PH24156A (en) 1990-03-22
DK352884A (da) 1985-01-20

Similar Documents

Publication Publication Date Title
DE2618822B2 (de) Anthracyclin-Glycoside und Verfahren zu deren Herstellung
EP0131942B1 (de) Anthracyclin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika
DE2432644A1 (de) Derivate von desoxystreptamin enthaltenden aminoglykosid-antibiotikumderivaten und verfahren zu ihrer herstellung
DE2047368A1 (de) Verfahren zur Herstellung von 9 (beta D Arabinofuranosyl) adenin 5 phos phat
EP0196628A2 (de) Ein neues Ansamycin-Antibiotikum, ein mikrobielles Verfahren zu seiner Herstellung und seine Verwendung als Arzneimittel
EP0286926B1 (de) Semisynthetische Rhodomycine, Verfahren zu ihrer Herstellung und ihre Verwendung als Zytostatika
DE2929058A1 (de) Anorganische salze von trimethylammoniumderivaten der polyenmakrolide, insbesondere anorganische salze von methylestern dieser derivate, und verfahren zu deren herstellung
DE3044970C2 (sv)
EP0064635B1 (de) Aminocyclitderivate, ihre Herstellung und sie enthaltende Arzneimittel
DE2731306C3 (de) 9-Desacetyl- und 9-Desacetyl-9-epi-daunorubicin, Verfahren zu deren Herstellung und deren Verwendung
EP0167954B1 (de) 1-Hydroxy-Cytorhodine, ein mikrobiologisches Verfahren zu ihrer Herstellung und ihre Verwendung als Cytostatika
DE3149608C2 (sv)
EP0186807B1 (de) Anthracyclin-Derivate, ein mikrobiologisches Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE2846383C3 (de) l-(2-Chloräthyl)-l-nitroso-3-(D-ribofuranosyl)-harnstoffe, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3524117A1 (de) Neue anthracyclin-tetrasaccharide, ein verfahren zu ihrer herstellung und ihre verwendung als cytostatik
DE2746209A1 (de) Neues antibiotikum und verfahren zu dessen herstellung
DE2208631C3 (de) N-Isobornyloxycarbonylcephalosporin C, Verfahren zu seiner Herstellung und Verwendung zur Herstellung von Cephalosporin C
DE3704659A1 (de) Moenomycin c(pfeil abwaerts)3(pfeil abwaerts)-derivate, verfahren zu ihrer herstellung und ihre verwendung als antibiotika
AT274249B (de) Verfahren zur Herstellung des neuen Scilliglaucosidin-19-ol-α-L-rhamnosids
DE3306505C2 (de) 4-Desmethoxy-13-dihydro-daunorubicin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
DE1493253C (sv)
AT226885B (de) Verfahren zur Herstellung von N1-Glykosiden des 5-Fluor-cytosins
DE3709337A1 (de) Neue anthracyclin-glycoside, ein verfahren zu ihrer herstellung und ihre verwendung als cytostatika
EP0299350A2 (de) Zytostatisch wirksame Anthracyclinderivate
DE3044971A1 (de) 4',4"'-dideoxyparomomycin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19850326

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRAEMER, HANS PETER, DR.

Inventor name: FEHLHABER, HANS-WOLFRAM, DR.

Inventor name: BERSCHEID, HANS GERD, DR.

Inventor name: HUBER, GERHARD, DR.

17Q First examination report despatched

Effective date: 19860609

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 30727

Country of ref document: AT

Date of ref document: 19871115

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3467350

Country of ref document: DE

Date of ref document: 19871217

ET Fr: translation filed
GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19880731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19900619

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19900625

Year of fee payment: 7

Ref country code: GB

Payment date: 19900625

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19900626

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19900704

Year of fee payment: 7

ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19900731

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19900906

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19900917

Year of fee payment: 7

Ref country code: CH

Payment date: 19900917

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19910714

Ref country code: AT

Effective date: 19910714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19910715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19910731

Ref country code: CH

Effective date: 19910731

Ref country code: BE

Effective date: 19910731

BERE Be: lapsed

Owner name: HOECHST A.G.

Effective date: 19910731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19920201

GBPC Gb: european patent ceased through non-payment of renewal fee
NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19920331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19920401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 84108305.8

Effective date: 19920210